Q2 FY2026 · ended Jun 30, 2026 · Revenue $6.32M, +124.3% YoY · Filed Aug 14, 2026
Emmaus Life Sciences, Inc. (EMMA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $6.3 million and net income of $1.3 million. Free cash flow was $1.7 million. As of Jun 30, 2026 it held $2.8 million in cash and investments and $26.7 million in total debt.
Revenue
$6.32M
+124.3% vs year-ago quarter
Net income
$1.34M
+218.0% vs year-ago quarter
Operating cash flow
$1.69M
+158.2% vs year-ago quarter
Free cash flow
$1.69M
+158.1% vs year-ago quarter
EPS
$0.02
+200.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
70.19M
+9.9% vs year-ago quarter
Net cash
$-23.88M
Q2 FY2026
Operating margin
29.3%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EMMA (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Torrance, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 822370
- Former names
- MYnd Analytics, Inc. (until Jul 12, 2019); CNS RESPONSE, INC. (until Dec 10, 2015); STRATIVATION, INC. (until Mar 1, 2007); SalesTactix, Inc. (until Aug 23, 2005); AGE RESEARCH INC (until Aug 5, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $6.3M | $2.0M | $3.9M | $3.4M | $2.8M |
| Operating income | $3.8M | -$823,000 | $886,000 | $695,000 | -$370,000 |
| Net income | $1.3M | -$3.3M | -$2.0M | -$2.1M | -$1.1M |
| Diluted EPS | $0.02 | -$0.05 | -$0.03 | -$0.03 | -$0.02 |
| Operating cash flow | $1.7M | -$344,000 | $2.2M | $409,000 | -$2.9M |
| Free cash flow | $1.7M | — | $2.2M | $409,000 | -$2.9M |
| Total assets | $16.4M | $18.7M | $21.4M | $20.8M | $23.3M |
| Total liabilities | $82.5M | $86.6M | $85.0M | $80.2M | $79.0M |
| Stockholders' equity | -$66.2M | -$67.9M | -$63.6M | -$59.5M | -$55.7M |
| Cash and investments | $2.8M | $1.1M | $2.1M | $293,000 | $886,000 |
| Total debt | $26.7M | $28.3M | $28.9M | $30.9M | $31.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
May 15, 2026 | May 15, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 17, 2026 | Apr 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 14, 2026 | Apr 13, 2026 |
All 1003 Emmaus Life Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.